

A study investigating the extraction of nicotine and flavors from tobacco free nicotine pods compared to tobacco based Swedish snus

Submission date 14/11/2017	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 21/11/2017	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 12/02/2024	Condition category Other	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Sweden displays the lowest prevalence of smoking in Europe, particularly among males. One explanation for the record-low low smoking prevalence is that snus has replaced cigarettes as the tobacco product of choice. Snus is a smokeless tobacco capable of rapidly delivering nicotine to the bloodstream and therefore may be more satisfactory among smokers than currently available pharmaceutical nicotine products. Snus remains a controversial product as it contains tobacco and is intended for recreational use. The tobacco in snus contains carcinogenic ingredients (that could cause cancer), but at very low amounts. Recently, a novel, non-tobacco-based nicotine product (ZYN®) has been developed. It is similar to snus however it contains no nitrosamines or polycyclic hydrocarbons (PAHs) which may potentially be carcinogenic. The overall safety of ZYN® is better than snus, however it only has a little bit less nicotine than snus. When comparing the nicotine content of different nicotine-containing products, it is important to consider that the nicotine extraction and uptake varies considerably depending on product type and formulation. Commercially available snus products have a nicotine content ranging between 1-2%. Previous studies have shown that on average about 15-20% of the total nicotine content is extracted and absorbed. Extraction is generally not linear with pouch size: it is larger with small compared to larger pouches, which suggests that surface area, saliva penetration and diffusion factors may be more important determinants of nicotine uptake than pouch weight. The nicotine delivery profile of a product is probably a main determinant of its efficacy to function as an alternative to cigarettes among current smokers. The aim of this study is to measure the nicotine delivery profile of ZYN® in comparison with commercially available snus products (which have a documented ability to replace cigarettes as a source of recreational nicotine among current tobacco consumers).

Who can participate?

Healthy volunteers aged over 19 who have used tobacco-based snus for over 1 year

What does the study involve?

The study compares the estimated in-vivo extracted dose of nicotine from a novel, non-tobacco-based nicotine pouch containing 3 or 6 mg of nicotine, with that from a 1 g Swedish snus pouch

containing 8 mg of nicotine. The study includes 14 doses of either ZYN® or snus. Participants report to the laboratory on separate days for 14 experimental interventions. All participants receive the same treatment in a randomised order. The amount of nicotine that is extracted from each dose is assessed.

What are the possible benefits and risks of participating?

There are no possible benefits of participating. The tested products are commercially available and only participants who are well acquainted with and used to the effects of nicotine will participate. The only side effects are the effects likely to be related to the nicotine exposure (such as salivation, nausea, and dyspepsia).

Where is the study run from?

CTC Clinical Trial Consultants AB (Sweden)

When is the study starting and how long is it expected to run for?

June 2017 to November 2017

Who is funding the study?

Swedish Match North Europe (Sweden)

Who is the main contact?

Mikael Staaf

mikael.staaf@swedishmatch.com

Contact information

Type(s)

Scientific

Contact name

Dr Mikael Staaf

Contact details

Swedish Match North Europe

Maria Skolgata 83

Stockholm

Sweden

SE-118 53

Additional identifiers

Protocol serial number

SM 17-01

Study information

Scientific Title

The in-vivo extraction of nicotine and flavor compounds from a single dose of a non-tobacco-based nicotine pouch (ZYN®) compared with conventional, tobacco-based Swedish snus among current, daily snus users

Study objectives

The aim of this study is to compare the estimated in-vivo extracted dose of nicotine from a novel, non-tobacco-based nicotine pouch containing 3 or 6 mg of nicotine, with that from a 1 g Swedish snus pouch containing 8 mg of nicotine. Nicotine extraction may serve as a proxy for the in vivo uptake of nicotine.

Ethics approval required

Old ethics approval format

Ethics approval(s)

EPN Uppsala, 13/09/2017, ref: Dnr 2017/318

Study design

Single-centre open randomized fourteen-way cross-over single dose administration

Primary study design

Interventional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Tobacco use not otherwise specified (NOS)

Interventions

The treatments are administered as single doses in a pre-determined computer-generated randomized order according to a four-sequence list. Participants are randomly allocated as to what order they receive the following doses:

1. ZYN® Smooth containing 3 mg nicotine per portion - 15 min single dose administration
2. ZYN® Smooth containing 3 mg nicotine per portion - 60 min single dose administration
3. ZYN® Smooth containing 6 mg nicotine per portion - 15 min single dose administration
4. ZYN® Smooth containing 6 mg nicotine per portion - 60 min single dose administration
5. ZYN® Smooth containing 3 mg nicotine per portion (alternative manufacturing process) - 15 min single dose administration
6. ZYN® Smooth containing 3 mg nicotine per portion (alternative manufacturing process) - 60 min single dose administration
7. ZYN® Smooth containing 6 mg nicotine per portion (alternative manufacturing process) - 15 min single dose administration
8. ZYN® Smooth containing 6 mg nicotine per portion (alternative manufacturing process) - 60 min single dose administration
9. ZYN® Wintergreen containing 3 mg nicotine per portion (Nicotine analysis) - 60 min single dose administration
10. ZYN® Wintergreen containing 3 mg nicotine per portion (Flavor analysis) - 60 min single dose administration
11. ZYN® Peppermint containing 3 mg nicotine per portion (Nicotine and Flavor analysis) - single dose 60 min administration
12. ZYN® Spearmint containing 3 mg nicotine per portion (Nicotine and Flavor analysis) - 60 min

single dose administration

13. Swedish portion snus PSWL 1.0 g (8 mg nicotine/g) - 15 min single dose administration

14. Swedish portion snus PSWL 1.0 g (8 mg nicotine/g) - 60 min single dose administration

The treatments are administered as single doses in a pre-determined randomised order. The participant keeps the pouch still between the upper lip and the gum for 15 or 60 minutes.

The total duration of the treatments and follow-up for all study arms is one day followed by 1-14 day(s) of wash-out (repeated for each dose time point) and follow-up seven days after the last dose, i.e. the total duration is different depending on the number of wash-out days.

Intervention Type

Other

Primary outcome(s)

Extracted dose of nicotine from each portion is measured by using GC-MS analysis and calculated by subtracting the residual amount after use from the mean of 10 unused portions. Used portions are freezed after dosing and analysis using GC-MS is performed at the end of the trial.

Key secondary outcome(s)

1. Pulse rate is measured using a pulsimeter at baseline, five, ten, 15, 30 and 60 minutes
2. Head buzz (head rush, "hit", feeling alert, overall "product strength" is measured using a 100-mm visual analogue scale (VAS) at preset time points up to 30 and 60 minutes, respectively, after study product administration (as a proxy for systemic uptake)
3. The extracted dose of flavor components are measured using GC-MS analysis and calculated by subtracting the residual amount after use from the mean of 10 unused portions. Used portions are freezed after dosing and analysis using GC-MS is performed at the end of the trial.
4. Adverse events are measured using patient interviews at predose, five, ten, 15, 30 and 60 minutes

Completion date

14/11/2017

Eligibility

Key inclusion criteria

1. Snus user, with a minimum weekly consumption of three or more snus cans (brands with nicotine content <1%) or two or more cans (brands with nicotine content >1%) since ≥1 year
2. Consent to participate voluntarily and sign Informed Consent Form prior to any study procedure
3. Healthy male/female, age ≥19. Female subjects should have a negative pregnancy test.
4. Willing and able to comply with study procedures
5. A heart rate increase ≥ 10 beats/min with first use of snus in the morning after overnight abstinence from any nicotine exposure

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. A history or presence of diagnosed hypertension or any cardiovascular disease
2. Surgery within 6 months of the screening visit that, in the opinion of the investigator, could negatively impact on the subject's participation in the clinical study
3. Any surgical or medical condition, which, in the judgment of the clinical investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug
4. Subjects who are pregnant

Date of first enrolment

14/09/2017

Date of final enrolment

22/09/2017

Locations**Countries of recruitment**

Sweden

Study participating centre

CTC Clinical Trial Consultants AB

Akademiska Sjukhuset Ingång 85 Våning 2

Uppsala

Sweden

SE-752 37

Sponsor information**Organisation**

Swedish Match North Europe

Funder(s)**Funder type**

Industry

Funder Name

Swedish Match North Europe

Results and Publications

Individual participant data (IPD) sharing plan

As this is a controlled clinical trial conducted according to GCP-IHC criteria the trialists are obliged and intend to keep all study data stored after completion of the study. However, they have not yet decided where and how this will be done. The data might be shared with relevant authorities. They might potentially also share de-identified data with other researchers on an ad hoc basis. The details and logistics of such data sharing has not yet been decided.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		15/02/2022	15/02/2022	Yes	No
Other unpublished results	clinical study report	20/12/2018	12/02/2024	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Protocol file		26/06/2017	01/12/2022	No	No